Funds of Euro38.7m
London - Ark Therapeutics raised Euro38.7 million through the sale of 31.9 million shares at 85p in a placing offer. Existing shareholders also sold 2.6 million at the issue price. The proceeds shall be used to fund the development of the company's existing clinical programmes. A Marketing Application Approval for Ark's gene therapy Cerepro against brain cancer is currently under review of the EMEA.